t(11; 18) (q21; q21) is a chromosomal aberration specific to low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, and generates the chimeric product apoptosis inhibitor 2 (API2)-MALT1, which has been suggested to play an important role in MALT lymphomagenesis. However, little is known about the characteristics of API2, MALT1, and API2-MALT1 proteins. We therefore investigated the subcellular localization and stability of these products. API2 was localized in the nucleus and the cytoplasm, and MALT1 and API2-MALT1 in the cytoplasm only. Western blot analysis showed that the products of API2 and MALT1 were unstable, while the API2-MALT1 product was stable. The API2 deletion mutants at the end of the C-terminal and the MALT1 deletion mutants at the end of the N-terminal were stable compared with the full-length products. These results indicate that the domains responsible for protein instability are located in the end of the C-terminal of API2 and in that of the N-terminal of MALT1, and also that API2-MALT1 became stable because it lacks these domains. It has been suggested that NF-jB activation plays an important role in the tumorigenesis of MALT lymphoma. Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-jB activating pathway, thus leading to MALT lymphomagenesis.
Introduction
Malignant lymphomas of mucosa-associated lymphoid tissue (MALT) account for about 7-8% of all B-cell lymphomas. Frequently, a background of chronic inflammation triggered by Helicobacter pylori infection or autoimmune disease, cause MALT lymphomas to arise in extranodal sites such as stomach, lung, thyroid gland, conjunctiva, salivary gland, gut, and skin (Isaacson and Spencer, 1987; Isaacson, 1999) . t(11; 18) (q21; q21) is the most frequent chromosomal aberration in low-grade MALT lymphomas (Ott et al., 1997) . While this abnormality is found in 18-36% of MALT lymphomas, it has never been identified in nodal or splenic marginal zone B-cell lymphomas or extranodal high-grade lymphomas (Ott et al., 1997; Baens et al., 2000; Motegi et al., 2000; Remstein et al., 2000; Inagaki et al., 2001; Yonezumi et al., 2001) . The frequency of t(11;18) (q21;q21) differs according to the site of origin of the tumor. While it has been frequently observed in tumors originating from lung, stomach, and colon, it has been rarely seen in tumors originating from conjunctiva and salivary and thyroid glands (Motegi et al., 2000; Remstein et al., 2000; Inagaki et al., 2001; Yonezumi et al., 2001) . t(11; 18) translocation results in the fusion of two genes, Apoptosis inhibitor 2 (API2) gene at 11q21 and MALT1 gene/MLT at 18q21 Dierlamm et al., 1999; Morgan et al., 1999; Suzuki et al., 1999) . API2 is a member of the inhibitor of apoptosis (IAP) family, which has an antiapoptotic effect (Roy et al., 1997) . API2 has three baculovirus IAP repeat (BIR) domains at its NH 2 -terminus, and has a caspase recruitment domain (CARD) and a RING finger domain at its carboxyl-terminus (Deveraux and Reed, 1999) . RING domain is known to have ubiquitin ligase activity (Huang et al., 2000; Yang et al., 2000) and BIR domains are thought to be necessary for the antiapoptotic effect of API2 (Roy et al., 1997) . MALT1 is a novel gene that was discovered at the translocation junction of t(11; 18) (q21; q21) Dierlamm et al., 1999; Morgan et al., 1999) . It is known that this gene has one death domain (DD), two immunoglobulin-like (Ig-like) domains, and one caspase-like domain (CLD) Dierlamm et al., 1999; Morgan et al., 1999; Uren et al., 2000) . As MALT1 is expressed in peripheral blood mononuclear cells, bone marrow, thymus, and lymph nodes, it is thought that MALT1 is related to cell differentiation and proliferation in hematopoietic-lymphoid cells . It was demonstrated that MALT1 and bc110 form a strong complex and that these proteins synergize in NF-kB activation. CLD of MALT1 was shown to be essential for the NF-kB activation (Uren et al., 2000; Lucas et al., 2001; McAllister-Lucas et al., 2001) , but the functions of the DD and Ig-like domains remain to be explored. t(11; 18) (q21; q21) has been studied in terms of its frequency in MALT lymphomas and association with this disease, but only a few studies have made a functional analysis of the API2-MALT1 protein. For this purpose, we constructed expression vectors and investigated the properties of API2, MALT1, and API2-MALT1 by means of Western blotting (WBA) and immunofluorescence microscopic analyses.
Results

Subcellular localization of API2, MALT1, and API2-MALT1 products
Immunofluorescence staining was used to study the subcellular localization of COS7 cells transiently transfected with API2, MALT1, API2-MALT1, and empty pcDNA3 ( Figure 1a -c, k). The API2 product was localized in the nucleus and the cytoplasm of the transfected cells. In some transfectants, API2 was also localized in the nucleolus. In contrast, the MALT1 and API2-MALT1 products were localized only in the cytoplasm of the transfected cells. During the experiments, it was recognized that the number of positive cells in API2 and MALT1 are different from those in API2-MALT1. API2-MALT1 products were detected in 2.2% of all cells, but API2 and MALT1 products in 0.4 and 0.2%, respectively. By adding MG132, a proteasome inhibitor, to the transfection experiments, the percentage of cells expressing API2 or MALT1 increased to 2.5 and 4.9%, respectively. The percentage of API2-MALT1-expressing cells did not differ significantly in the presence of MG132 (1.6%). These results suggest that the API2 and MALT1 products are unstable. The experiments were repeated three times, and similar results were obtained. The instability of API2 and MALT1 was further confirmed by WBA.
Western blot analysis
The stability of API2-MALT1, API2, and MALT1 products were examined by WBA (Figure 2 ). API2-MALT1 was detected 24 h after the transfection (Figure 2a, lane 4) . The presence of proteasome inhibitor MG132 did not result in a significant increase in the products (Figure 2a , lanes 5-10). The API2 product was not detected in the cells without MG132 (Figure 2b , lanes 4, 5, 7, and 9), but became detectable after the addition of MG132 (Figure 2b, lanes 6, 8, and 10) . Similarly, MALT1 products could not be detected without MG132 (Figure 2c , lanes 4, 5, 7, and 9), but could be detected 12 h after the addition of MG132 (Figure 2c , lanes 8 and 10). These results indicated that API2 and MALT1 products were unstable while the API2-MALT1 product was stable, and suggested that truncation of API2 and MALT1 might increase their stability. We therefore constructed API2 and MALT1 deletion mutants (Figure 3a) , and investigated the stability of these mutants by means of WBA ( Figure  3b , c). The products of the two API2 deletion mutants API2-RING (À), API2-CARD (À) could be detected without MG132 (Figure 3b , lanes 6, 7, 9, and 10), indicating that the RING domain is responsible for its instability. The products of the three MALT1 deletion mutants MALT1-Ig(1 2), MALT1-Ig(2), MALT1-CLD, were also detectable without MG132 (Figure 3c , lanes 7, 9, 10, 12, and 13). MALT1-CLD was expressed more than the other two mutants (Figure 3c , lanes 6-14). MG132 significantly increased the level of MALT1-Ig (1 2) and MALT1-Ig(2) products (Figure 3c , lanes 7, 8, 10, and 11), but did not increase that of MALT1-CLD (Figure 3c, lanes 13 and 14) . These results indicated that the region deleted in MALT1-Ig(1 2) was partially responsible for the instability of MALT1, and that the Ig-like domains of MALT1 were mainly responsible for its instability. We investigated the half-life of API2, MALT1, and API2-MALT1 by adding actinomycin D (Figure 3d ). The half-life of API2 and MALT1 could not be determined because these products were not detectable, but that of API2-MALT1 was found to be 7.0 h.
Subcellular localization of deletion mutants of API2, MALT1, and API2-MALT1
We also examined whether the deletion mutants changed their localization pattern in relation to their respective full-length products. Both deletion mutants of API2 were found to be localized in the nucleus and the cytoplasm (Figures 1d, e) . This pattern was identical to the localization of the full-length API2 ( Figure 1b ). All three MALT1 deletion mutants were localized in the cytoplasm (Figure 1f , g, and h). This pattern was identical to the one with the full-length MALT1 ( Figure 1c ). These results suggested that the domains deleted from API2 or MALT1 did not determine intracellular localization of the API2-MALT1 chimeric protein, but that the C-terminal region of MALT1 did ( Figure 1a ). We therefore constructed C-terminal deletion mutants of API2-MALT1 ( Figure 3a ) and examined their localization patterns. It was demonstrated that both deletion mutants of API2-MALT1 localized in the nucleus and the cytoplasm (Figure 1i , j). Thus, the region responsible for subcellular localization of API2-MALT1 is located in the C-terminal region of MALT1.
API2-MALT1 and apoptosis
To investigate whether API2-MALT1 chimeric protein has an antiapoptotic effect, we established stable API2-MALT1 transfectants with the murine IL-3-dependent hematopoietic Ba/F3 cells, and induced apoptosis by means of IL-3 deprivation or ultraviolet (UV) irradiation. The API2-MALT1 transfectant showed the same dependence on IL-3 for both viability and proliferation as did wild-type Ba/F3 and vector control ( Figure 4a ). As for apoptosis resulting from UV irradiation, the viability of both wild-type and API2-MALT1 transfectant quickly decreased without any obvious difference ( Figure 4b ). These results suggested that API2-MALT1 had no antiapoptotic effect on Ba/F3 cells to protect them against apoptosis by IL-3 deprivation or UV irradiation.
Discussion
We have shown that API2 localized in both nucleus and cytoplasm, while MALT1 and API2-MALT1 localized in the cytoplasm only. The localization pattern of API2 deletion mutants was found to be similar to that of full-length API2. Localization pattern of MALT1 deletion mutants was also found to be similar to that of full-length MALT1. These results suggest that the MALT1 carboxyl-terminus determines the localization of API2-MALT1 chimeric products in the cytoplasm. In fact, C-terminal deletion mutants of API2-MALT1 localized in not only the cytoplasm but also the nucleus. It is known that some virus-derived IAP can be oligomerized by BIR-BIR interaction (Hozak et al., 2000) . As oligomerized MALT1 has been shown to activate NF-kB ), API2-MALT1 (2) (j) and pcDNA3 (k). Anti-flag antibody was used for identification of all the constructs. See Figure 3a for the constructs Stability and subcellular localization of API2-MALT1 K Izumiyama et al protein may be oligomerized through its BIR-dependent interactions and thus activates NF-kB through the oligomerized MALT1 carboxyl-termini. We could demonstrate that API2-MALT1 localizes in the cytoplasm, which suggests that the action takes place in the cytoplasm. It will therefore be necessary to investigate what kind of proteins API2-MALT1 molecules directly bind within the cytoplasm and how they activate NF-kB.
During immunofluorescence microscopic analysis and Western blotting, API2 and MALT1 products could be visualized as the result of using the proteasome inhibitor MG132. These results not only confirmed the reports that API2 is degraded via the ubiquitin-proteasome pathway (Yang et al., 2000) , but also suggested that MALT1 is degraded as well via the same pathway. Two API2 deletion mutants, API2-RING (À) and API2-CARD (À), were stable against proteasome-mediated degradation when compared with full-length API2. Both API2-RING (À) and API2-CARD (À) have deletion of RING finger domain in common. The activity of some ubiquitin ligases (E3) is reportedly dependent on the RING finger domain , and Yang et al. 2000) showed that removal of the RING domain from API2 could inhibit API2 ubiquitination and its degradation (Yang et al., 2000) .
All three MALT1 deletion mutants were also more stable than full-length MALT1. We therefore considered aa 1-126 of MALT1, containing DD, to be related to the ubiquitin-proteasome pathway. The quantity of the product of MALT1-CLD was significantly greater than that of MALT1-Ig(1 2) and MALT1-Ig(2). While the products of MALT1-Ig(1 2) and MALT1-Ig(2) could be increased by the addition of MG132, the quantity of the MALT1-CLD product did not change. These results suggest that two Ig-like domains of MALT1 are also related to instability against proteasome-mediated degradation. API2-MALT1 was detected without the presence of MG132, indicating that API2-MALT1 products are more stable than those of API2 and MALT1. The presence of MG132 did not affect the quantity of API2-MALT1 products. These results suggest that API2-MALT1 products are stable against proteasome-mediated degradation, and imply that API2-MALT1 becomes stable in the absence of the domains of API2 and MALT1 that are associated with protein instability. Examination of clinical samples has determined that both API2 and MALT1 have four breakpoints and that there are eight variants of API2-MALT1 Dierlamm et al., 1999; Baens et al., 2000; Kalla et al., 2000; Motegi et al., 2000; Remstein et al., 2000; Inagaki et al., 2001; Yonezumi et al., 2001) . The stability of the API2-MALT1 variants may be different because the domains deleted from API2 or MALT1 are variable, but all variants of API2-MALT1 products are likely to be more stable than the full-length products of API2 and MALT1.
MALT1 alone cannot activate NF-kB, but API2-MALT1 can achieve NF-kB activation without any coexpression of molecules such as bc110. As API2-MALT1 is stable, the NF-kB activating pathway may be continuously stimulated.
It has been shown that CLD of API2-MALT1 is responsible for making NF-kB activation possible (Uren et al., 2000; Lucas et al., 2001) . All of the eight API2-MALT1 variants found to date conserve CLD, indicating that all API2-MALT1 variants can activate NF-kB, and that this activation plays an important role in the tumorigenesis of MALT lymphomas. In addition, bc110 overexpression resulting from t(1; 14) (q22; q32), one of the typical chromosomal aberrations in MALT lymphomas, can also activate NF-kB (Willis et al., 1999; Zhang et al., 1999) . As NF-kB activity has been shown to inhibit apoptosis (Barkett and Gilmore 1999) , we hypothesized that API2-MALT1 may have an antiapoptotic function. We therefore transfected the API2-MALT1 gene to the murine B-cell line Ba/F3 (Palacios and Steinmetz, 1985) , and induced apoptosis by IL-3 deprivation or UV irradiation. However, no antiapoptotic effect of API2-MALT1 was observed. The reason for this may be that the differentiation stage of the MALT lymphoma cell, which originates from the postgerminal center B cell, is different from that of Ba/F3 originating from the pre-B cell. In conclusion, we could demonstrate that API2-MALT1 products were very stable and that the action takes place in the cytoplasm. We also showed that truncation of API2 and MALT1 increases API2-MALT1 stability against the ubiquitin-proteasome pathway. This leads to the hypothesis that stabilized API2-MALT1 products may continuously stimulate the NF-kB activating pathway, thus leading to MALT lymphomagenesis.
Materials and methods
Constructs
The fragments of all the constructs except for MALT1 were amplified by RT-PCR from peripheral blood lymphocytes or patient samples. For the PCR a 100 ng template cDNA was diluted up to 100 ml with 1 Â ThermoPol reaction buffer (10 mm KCl, 10 mm (NH 4 ) 2 SO 4 , 20 mm Tris-HCl (pH 8. 
0 , 521C, NheI/ApaI, XbaI/ApaI. To construct the pcDNA3-MALT1-flag (66-2504 bp), full-length MALT1 cDNA was constructed based on clones isolated from a KOCL-33 cell cDNA library . The 5 0 fragment of the MALT1 cDNA clone was digested with BamHI and HindIII and cloned into the pBS vector at the BamHI/HindIII sites. For PCR amplification of the 3 0 fragment of MALT1, the 100 ng template cDNA was diluted up to 100 ml with 1 Â ThermoPol reaction buffer, 1 mm of each primer (5 0 primer: 5 0 -AGGAGCAGAAGCTTTTGAAATC-3 0 and 3 0 primer: 5 0 -CCGCTCGAGTTTTTCAGAAATTCTGAGCCTGTC-3 0 ), 200 mm of each dNTP, and 2.5 U of the polymerase mixture. Reaction times consisted of denaturation at 951C for 60 s, annealing at 541C for 60 s, and extension at 721C for 90 s in 35 cycles. The fragment was digested with HindIII and XhoI and ligated into the pBS-5 0 MALT1 vector at the HindIII/XhoI site. This full-length MALT1 was then cloned into the BamHIXhoI sites of the pcDNA3-Flag vectors. The competent cells transformed with API2-MALT1 or MALT1-Ig(1 2) were cultured at 301C, while those of the other constructs were cultured at 371C. The sequences of the all constructs were confirmed with the ABI PRISM BigDye TM Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer, Foster City, CA, USA).
Cell culture and transfection
COS7 cells were grown in Iscove's medium supplemented with 5% fetal calf serum (FCS) and maintained in a 5% CO 2 incubator at 371C. For WBA and immunofluorescence staining studies, COS7 cells were transiently transfected with Effectene (QIAGEN KK, Tokyo, Japan) according to the manufacturer's instructions. The transfection efficiency was standardized by cotransfection with the b-galactosidase (b-gal) expression plasmid (pCMVbgal) (Kiyono et al., 1994) . A control dish of COS7 cells from each transfection experiment was fixed with 0.25% gultaraldehyde and stained with 0.2% 5-bromo-4-chloro-3-indolyl-b-d-galactopyranoside (X-gal), 2 mm MgCl 2 , 5mm K 4 [Fe(CN) 6 ]/3H 2 O, 5 mm K 3 [Fe (CN) 6 ] in phosphate-buffered saline (PBS) at 371C for 3 h. The ratio of blue stained to 500 cells served as an index for transfection efficiency. Ba/F3 cells used for the apoptosis assay were maintained in RPMI 1640 medium with 5% FCS contained with 10% WEHI-3BD conditioned medium as a source of IL-3, and maintained in a 5% CO 2 incubator at 371C. The cells were then transfected with linearized plasmids with electroporation method using a Gene Pulser (BioRadJapan, Tokyo, Japan) at 960 mF, 450 V and selected in medium containing 1 mg/ml G418. Transfectants were confirmed to have API2-MALT1 protein by WBA, and were used for the experiments.
Immunofluorescence staining COS7 cells were grown on circular slide glasses (12 mm in diameter) in a 24-well dish, and transfection was carried out with the Effectene method. At 48 h after transfection, the cells were fixed in 3.7% formaldehyde in PBS for 10 min at room temperature. After washing with PBS, the cells were permeabilized in 100% methyl alcohol for 10 min at 41C, and after another washing with PBS, anti-FLAG M2 monoclonal antibody (Sigma, St Louis, MO, USA) was applied at 4 mg/ ml in PBS for 2 h at room temperature. The cells were then washed three times with PBS, and incubated with FITCconjugated goat anti-mouse IgG (Immuno Biological Laboratories, Fujioka, Japan), diluted to 1 : 100 in PBS, for 2 h at room temperature. The specimens were incubated in 0.1 mg/ml of propidium iodide in PBS for 5 min and washed three times with PBS, and then mounted in PermaFluor aqueous mounting medium (Immunon, Pittsburgh, PA, USA). The specimens were finally examined by means of confocal fluorescence microscopy (Olympus, Tokyo, Japan) and a laser scanning system (Radiance 2100, Bio-Rad-Japan, Tokyo, Japan). The percentage of positive cells was calculated by counting 1200 cells.
Western blot analysis
COS7 cells in 6 cm dishes were transfected with the Effectene method, and 24 h later, Iscove's medium containing 10 mmol/l proteasome inhibitor, with or without MG132, was added to the dishes. At 0-24 h after the MG132 addition, the cells were resuspended in 100 ml of a 2Â SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (125 mm Tris, pH6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.02% bromophenol blue) and boiled for 10 min. A measure of 10 ml aliquots were subjected to 10% SDS-PAGE, and transferred onto PVDF membranes (Millipore, Bedford, MA, USA). The membranes were then blocked with blocking buffer (3% BSA and 2% nonfat drymilk in PBS containing 0.05% NaN 3 ) for 1 h at 371C, and washed with 0.05% Tween-20 in PBS (T-PBS). They were next incubated overnight with 4 mg/ml of anti-FLAG M2 monoclonal antibody (Sigma) in blocking buffer at 41C, washed extensively in T-PBS and incubated with horseradish peroxidase-conjugated anti-mouse IgG (Immuno Biological Laboratories), diluted at 1 : 1000 in blocking buffer without 0.05% NaN 3 . After 1 h incubation at room temperature, the membranes were washed with T-PBS, and visualized with an ECL detection kit (Amersham Japan, Tokyo, Japan).
Half-life analysis
A total of 5.0 Â 10 5 COS7 cells in 10 cm dishes were transfected with the Effectene method as described earlier, and 48 h later the cells were resuspended in 13 ml of Iscove's medium supplemented with 5% FCS in a polypropylene round-bottom tube. After thorough stirring, 1 ml of the sample for 'time 0' was placed in a sterile 1.5 ml Eppendorf tube. The remainder, with the addition of 10 mm of actinomycin D (Wako, Osaka, Japan), was returned to the 371C CO 2 incubator. At 2, 4, 6, and 8 h after the addition of actinomycin D, 1 ml of the sample was placed in Eppendorf tube after thorough stirring. Each sample was then centrifuged at 3000 g for 1 min and the cells were resuspended in 100 ml of a 2 Â SDS-PAGE sample buffer (125 mm Tris, pH6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.02% bromophenol blue) and boiled for 5 min. WBA was performed as described earlier.
The half-life of API2-MALT1 was calculated by plotting the quantity of the product and measuring the time needed to reach 50% of the quantity before the actinomycin D was added.
MTS assay and induction of apoptosis
Ba/F3 cells were treated with IL-3 replacement or UV irradiation to induce apoptosis. The MTS assay (CellTiter 96 TM ; Aqueous Non-Radioactive Cell Proliferation Assay kit, Promega, Madison, WI, USA) was used for assessment. Briefly, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxylmethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and an electron coupling reagent (phenazine methosulfate, PMS) were added to the samples and incubated for 90 min. Then the optical density was measured with an ELISA plate reader using 655 nm as the reference wavelength and 490 nm as the test wavelength. For each culture condition, samples were prepared in quadruplicate. To study IL-3 dependency, Ba/F3 cells were cultured in Iscove's medium supplemented with 5% FCS and various percentages of WEHI-3BD conditioned medium (0, 1, 3, and 10%). A total of 1 Â 10 5 /200 ml cells were placed in the wells of 96-well flatbottom plates and then incubated at 371C in 5% CO 2 . The MTS assay was used for assessment on days 1-4. For the UVinduced apoptosis assay, 25 Â 10 4 cells/ml Ba/F3 cells in 100-mm dishes were exposed to UV irradiation (4 J/m 2 , 20 J/m 2 ) with a Stratalinker TM UV Crosslinker 1800 (Stratagene, La Jolla, CA, USA). After UV irradiation, the cells were placed in 96-well flat-bottom plates and incubated at 371C in 5% CO 2 . The MTS assay was used for assessment at 1. 5, 4, 8, 24, 48 , and 72 h after irradiation.
